Safety and Pharmacokinetics Study of HRS-1893 Tablets in Healthy Subjects and Those With Impaired Kidney Function
PHASE1CompletedINTERVENTIONAL
Enrollment
24
Participants
Timeline
Start Date
February 11, 2025
Primary Completion Date
July 23, 2025
Study Completion Date
July 23, 2025
Conditions
Hypertrophic Cardiomyopathy
Interventions
DRUG
HRS-1893
HRS-1893 tablets.
Trial Locations (1)
610072
Sichuan Provincial People's Hospital, Chengdu
All Listed Sponsors
lead
Shandong Suncadia Medicine Co., Ltd.
INDUSTRY
NCT06775834 - Safety and Pharmacokinetics Study of HRS-1893 Tablets in Healthy Subjects and Those With Impaired Kidney Function | Biotech Hunter | Biotech Hunter